Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720–8.

Article  CAS  PubMed  Google Scholar 

Weiden PL, Flournoy N, Sanders JE, Sullivan KM, Thomas ED. Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transpl Proc. 1981;13:248–51.

CAS  Google Scholar 

Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–62.

Article  CAS  PubMed  Google Scholar 

Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N. Engl J Med. 1986;314:729–35.

Article  CAS  PubMed  Google Scholar 

Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13:132.

Article  CAS  PubMed  Google Scholar 

Nagler A, Mohty M. In 2022, which is preferred: haploidentical or cord transplant? Hematol Am Soc Hematol Educ Program. 2022;2022:64–73.

Article  Google Scholar 

Nakamae H. Systematic overview of HLA-matched allogeneic hematopoietic cell transplantation with post-transplantation cyclophosphamide. Int J Hematol. 2022;116:465–81.

Article  CAS  PubMed  Google Scholar 

Bolaños-Meade J, Reshef R, Fraser R, Fei M, Abhyankar S, Al-Kadhimi Z, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019;6:e132–e143.

Article  PubMed  PubMed Central  Google Scholar 

Bolaños-Meade J, Hamadani M, Wu J, Al Malki MM, Martens MJ, Runaas L, et al. Post-transplantation Cyclophosphamide-based graft-versus-host disease prophylaxis. N. Engl J Med. 2023;388:2338–48.

Article  PubMed  PubMed Central  Google Scholar 

McDonald GB, Sandmaier BM, Mielcarek M, Sorror M, Pergam SA, Cheng GS, et al. Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: Comparing 2003–2007 versus 2013–2017 cohort. Ann Intern Med. 2020;172:229–39.

Article  PubMed  PubMed Central  Google Scholar 

Stern M, de Wreede LC, Brand R, van Biezen A, Dreger P, Mohty M, et al. Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis. Leukemia. 2014;28:2235–40.

Article  CAS  PubMed  Google Scholar 

Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transpl. 2012;18:1727–33.

Article  Google Scholar 

Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia. 2012;26:2462–8.

Article  CAS  PubMed  Google Scholar 

Gagelmann N, Bacigalupo A, Rambaldi A, Hoelzer D, Halter J, Sanz J, et al. Haploidentical stem cell transplantation with posttransplant cyclophosphamide therapy vs other donor transplantations in adults with hematologic cancers: a systematic review and meta-analysis. JAMA Oncol. 2019;5:1739–48.

Article  PubMed  PubMed Central  Google Scholar 

Shimoni A, Labopin M, Angelucci E, Blaise D, Ciceri F, Koc Y, et al. The association of graft-versus-leukemia effect and graft-versus-host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML. Bone Marrow Transpl. 2022;57:384–90.

Article  CAS  Google Scholar 

Baron F, Labopin M, Tischer J, Raiola AM, Vydra J, Blaise D, et al. GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT. J Hematol Oncol. 2023;16:10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl. 2020;55:1114–25.

Article  CAS  Google Scholar 

Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825–8.

CAS  Google Scholar 

Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE, et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med. 1980;69:204–17.

Article  CAS  PubMed  Google Scholar 

Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assos. 1958;53:457–81.

Article  Google Scholar 

Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.

Article  CAS  PubMed  Google Scholar 

Baron F, Labopin M, Savani BN, Beohou E, Niederwieser D, Eder M, et al. Graft-versus-host disease and graft-versus-leukaemia effects in secondary acute myeloid leukaemia: a retrospective, multicentre registry analysis from the Acute Leukaemia Working Party of the EBMT. Br J Haematol. 2020;188:428–37.

Article  PubMed  Google Scholar 

Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang MJ, Wang H, et al. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv. 2019;3:670–80.

Article  PubMed  PubMed Central  Google Scholar 

Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, et al. National marrow donor program-sponsored multicenter, Phase II Trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant Cyclophosphamide. J Clin Oncol. 2021;39:971–1982.

Article  Google Scholar 

Rimando J, McCurdy SR, Luznik L. How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond. Blood. 2023;141:49–59.

Article  CAS  PubMed  Google Scholar 

Luznik L, Pasquini MC, Logan B, Soiffer RJ, Wu J, Devine SM, et al. Randomized Phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. J Clin Oncol. 2022;40:356–68.

Article  CAS  PubMed  Google Scholar 

McCurdy SR, Kanakry CG, Tsai HL, Kasamon YL, Showel MM, Bolaños-Meade J, et al. Grade II Acute Graft-versus-host disease and higher nucleated cell graft dose improve progression-free survival after HLA-Haploidentical transplant with post-transplant Cyclophosphamide. Biol Blood Marrow Transpl. 2018;24:343–52.

Article  CAS  Google Scholar 

McCurdy SR, Kanakry CG, Tsai HL, Gojo I, Smith BD, Gladstone DE, et al. Development of Grade II acute graft-versus-host disease is associated with improved survival after Myeloablative HLA-matched bone marrow transplantation using single-agent post-transplant Cyclophosphamide. Biol Blood Marrow Transpl. 2019;25:1128–35.

Article  CAS  Google Scholar 

Negrin RS. Graft-versus-host disease versus graft-versus-leukemia. Hematol Am Soc Hematol Educ Program. 2015;2015:225–30.

Article  Google Scholar 

Teshima T, Hashimoto D. Separation of GVL from GVHD -location, location, location. Front Immunol. 2023;14:1296663.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gale RP, Fuchs EJ. Is there really a specific graft-versus-leukaemia effect? Bone Marrow Transpl. 2016;51:1413–5.

Article  CAS  Google Scholar 

Wachsmuth LP, Patterson MT, Eckhaus MA, Venzon DJ, Gress RE, Kanakry CG. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;129:2357–73.

Article  PubMed  PubMed Central